Compares deucravacitinib and apremilast in adults with plaque psoriasis in Japan
Observes adults with plaque psoriasis in Japan treated with deucravacitinib or apremilast.
Plain-language title generated from the registry record
Registry title: A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)
Key facts
- Where
- Fukuoka and Minato-ku, JapanSee the 2 sites
Where in Japan
- Fukuoka University HospitalFukuoka, JapanTaking people
- Mebix. IncMinato-ku, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06382987
- Record updated
- 25 April 2024
- Original description
This is a prospective, observational, real-world study of adult participants in Japan with physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or apremilast.Read full original descriptionShow less
Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect) - A Real-World, Prospective, Observational Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan
This is a prospective, observational, real-world study of adult participants in Japan with physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or apremilast.
Inclusion: Japanese adult participants aged 18 years old or older; Physician-reported diagnosis of plaque psoriasis; Newly initiating deucravacitinib or apremilast according to the label; Participants who have signed informed consent.
Exclusion: Previous treatment experience with the treatment of interest (e.g. patients who have history of apremilast will not be eligible to be enrolled in apremilast arm of the study and similar for deucravacitinib); Participants currently participating in or planning to participate in an interventional clinical trial; Patients enrolled in deucravacitinib post-marketing surveillance study (ClinicalTrial.gov ID: NCT05633264).